{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-037298","form_type":"8-K","ticker":"PDSB","cik":"0001472091","company_name":"PDS Biotechnology Corp","filed_at":"2026-09-22T12:05:08+00:00","discovered_at":"2026-09-22T12:10:01.131033+00:00","generated_at":"2026-09-22T12:10:30.412616+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"PDS Biotech publishes Phase 2 VERSATILE-002 results in JAMA Oncology; mOS 39.3 months in ICI-naive HNSCC","bullets":["mOS of 39.3 months for CPS≥1 ICI-naive patients vs 17.9 months for pembrolizumab SOC.","ORR 36% vs 19% published for pembro; 13.8% Grade≥3 TRAEs vs 17%.","PIPE financing of up to $22.3M led by Nant Capital; NantWorks gets one-year exclusive license negotiation right for PDS0101.","Company prioritizes PDS0301 in mCRC and pursues partnership for PDS0101."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-037298","json":"https://secwatch.observer/filing/0001140361-26-037298.json","markdown":"https://secwatch.observer/filing/0001140361-26-037298.md","text":"https://secwatch.observer/filing/0001140361-26-037298.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126037298/0001140361-26-037298-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1472091/000114036126037298/ef20082545_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-22T12:10:30.412616+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}